Welcome to our dedicated page for AtriCure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on AtriCure stock.
AtriCure, Inc. (symbol: ATRC) is a leading provider of cutting-edge medical technologies aimed at treating atrial fibrillation (Afib) and related conditions. With over 33 million people affected by Afib globally, AtriCure stands at the forefront of developing innovative solutions to combat this prevalent health issue. Electrophysiologists and cardiothoracic surgeons around the world rely on AtriCure's products to reduce complications associated with Afib.
The company's flagship product, the Isolator® Synergy™ Ablation System, is notably the first and only device approved by the FDA for the treatment of persistent Afib. Additionally, the AtriClip Left Atrial Appendage Exclusion System holds the title of the most widely sold LAA management device globally, with over 100,000 units implanted to date.
AtriCure's diverse product line includes solutions for Cryoablation, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, among others. They also offer a range of minimally invasive ablation devices and access tools catering to the increasing demand for less invasive cardiac and thoracic surgeries. Their products are distributed to medical centers through a combination of a direct sales force and a network of distributors.
Geographically, the majority of AtriCure's revenue is generated from the United States. The company continues to expand its impact through ongoing projects, research, and partnerships aimed at improving patient outcomes and advancing the field of cardiac surgery.
For more detailed information about AtriCure's latest developments, visit their official website at AtriCure.com or follow them on Twitter @AtriCure.
AtriCure, Inc. (Nasdaq: ATRC) announced preliminary financial results for Q4 2022 and provided 2023 guidance. Q4 revenue is expected at
AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation and related conditions, announced participation in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 7:30 am PST. The presentation can be accessed through the company’s Investors webpage. AtriCure is renowned for its innovative technologies, including the Isolator® Synergy™ Ablation System and AtriClip® devices, which are used worldwide for the management of Afib, affecting over 37 million people globally.
AtriCure, Inc. (NASDAQ: ATRC) has announced its participation in the 34th Annual Piper Sandler Healthcare Conference. The company is set to present on November 30, 2022, at 9:30 a.m. Eastern Time. A live audio webcast can be accessed via the Investors section on AtriCure's website. AtriCure specializes in surgical treatments for atrial fibrillation (Afib) and related conditions, providing innovative technologies including the FDA-approved Isolator® Synergy™ Ablation System and AtriClip® devices for left atrial appendage management.
AtriCure, Inc. (Nasdaq: ATRC) reported third quarter 2022 revenue of $83.2 million, an 18.1% increase from the previous year. U.S. revenue rose to $69.8 million, up 21.3%, driven by strong sales of the cryoSPHERE® probe and AtriClip® Flex·V® device. International revenue grew by 4.2% to $13.4 million. However, the company posted a loss from operations of $10.7 million, and adjusted EBITDA was negative at $0.7 million. Full-year guidance predicts revenue between $328 million and $333 million with an adjusted loss per share of $1.10 to $1.12.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in major investor conferences. Management will present at the Stifel 2022 Healthcare Conference on November 16, 2022, at 11:30 a.m. ET, with a live audio webcast available on their website. Additionally, they will host investor meetings at the Canaccord Genuity Medtech Forum on November 17, 2022. AtriCure provides innovative technologies including the Isolator® Synergy™ Ablation System and AtriClip® for Afib treatment, affecting over 37 million people worldwide.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced it will release its third quarter 2022 financial results on November 1, 2022, at 4:30 p.m. Eastern Time. The company invites investors to join an audio webcast to discuss the results, accessible on their corporate website. AtriCure is known for its innovative technologies, such as the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, which are widely used for Afib treatment and related conditions.
AtriCure, Inc. (NASDAQ: ATRC) announced an investor education webcast scheduled for September 28, 2022, at 2:00 p.m. ET, focusing on Hybrid AF Therapy. The webcast will feature insights from management and leading experts, alongside an interactive Q&A session. Interested participants can register on the company’s website. AtriCure is recognized for its innovative solutions addressing atrial fibrillation (Afib), with products such as the Isolator® Synergy™ Ablation System and AtriClip® LAA Exclusion System. These technologies cater to a market affecting over 33 million people globally.
AtriCure, Inc. (NASDAQ: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 1:30 p.m. Eastern Time. The event will be accessible via a live audio webcast on the company’s website. AtriCure specializes in innovative technologies for Afib treatment, with over 33 million people affected worldwide. Its FDA-approved Isolator® Synergy™ Ablation System leads the market in persistent Afib treatment.
AtriCure, Inc. (Nasdaq: ATRC) reported a strong second quarter of 2022 with revenues reaching $84.5 million, a growth of 18.4% compared to the previous year. U.S. sales rose by 18.6% to $71.3 million, driven by significant demand for products like the cryoSPHERE® probe and AtriClip® devices. However, the company recorded a loss from operations of $13.7 million with an adjusted EBITDA loss of $3.2 million. For 2022, AtriCure anticipates revenues between $323 million and $333 million, reflecting 18% to 21% growth over 2021.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib) and related conditions, has announced participation in two investor conferences. The management will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 10:00 a.m. ET. Additionally, they will engage in meetings at the 7th Annual Needham Virtual Med Tech & Diagnostics Conference on August 15, 2022. AtriCure is known for its innovative technologies, including the first FDA-approved device for persistent Afib treatment and widely used devices for left atrial appendage management.
FAQ
What is the current stock price of AtriCure (ATRC)?
What is the market cap of AtriCure (ATRC)?
What does AtriCure, Inc. specialize in?
What is the Isolator® Synergy™ Ablation System?
What is AtriClip?
How does AtriCure distribute its products?
What types of products does AtriCure offer?
Where does AtriCure generate most of its revenue?
Are AtriCure’s products used internationally?
What makes AtriCure's products unique?
Where can I find more information about AtriCure?
What are AtriCure’s latest achievements?
